
Big Pharma’s push to cut 340B will reduce services for low-income patients, harm local healthcare and cost states billions. This greed will raise drug prices, worsen health disparities, and strain communities. See the state-by-state impact and join the fight to protect 340B.
To counter PhRMA’s misinformation, Genesis partnered with The Sage Policy Group to analyze the proposed 340B cuts’ economic impact on patients and FQHCs nationwide and by state.
State Reports
Below are reviews reports with an analysis of the federal government’s 340B Drug Pricing program and how the impact of PhRMA’s proposed changes would impact each state. The reports are provided by the SAGE Policy Group’s analysis of each state and can be accessed below.
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
American Samoa
Guam
Puerto Rico
Virgin Islands
Washington DC